Skip to content

Dietary Reversal of the Reprometabolic Syndrome

Dietary Reversal of the Reprometabolic Syndrome

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07227766
Acronym
LFD
Enrollment
30
Registered
2025-11-13
Start date
2024-08-10
Completion date
2029-12-30
Last updated
2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Obesity & Overweight

Keywords

Infertility, Reproductive Hormones, Low-Fat Diet, Obesity, Hypothalamic-pitutary-ovarian axis

Brief summary

This study proposes to test the specific question that a eucaloric, low-fat diet given to women with obesity will result in an increase in reproductive hormones.

Detailed description

This an open-label, multi site study in pre-menopausal women aged 18-40 years old with a history of regular menstrual cycles (25-35 days long) of high BMI. The objective of the study will be to determine the effects of a one month long, eucaloric low-fat diet on reproductive hormone levels in women with a high BMI. The study will occur over 4 menstrual cycle (approximately 4 months). During the study the participants will have a pre-diet cycle where no food will be consumed, an on-diet cycle where the customized low-fat diet will be consumed, and two post diet cycles. First morning voided urine will be collected during all four cycles along with 3 blood draws during the study. Participants will be asked to use a reliable barrier method of birth control or abstain from intercourse during the study.

Interventions

DIETARY_SUPPLEMENTLow-fat diet

Participants will eat a one-month eucaloric high-fat diet.

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Normal TSH and prolactin * Regular menstrual cycles every 25-40 days * No history of chronic disease affecting hormone production, metabolism or clearance * No use of reproductive hormones, or medications/supplements known to impact them, within 3 months of enrollment * Use of a reliable method of contraception (female or male partner sterilization, IUD, abstinence, diaphragm or cervical cap) * Normal ovarian reserve (AMH of 0.5ng/ml or greater) * Normal testosterone levels at screening or absence of clinical evidence of hyperandrogenemia (acne, facial hirsutism \[defined as Ferriman-Gallwey score\>8\] or alopecia)

Exclusion criteria

* Baseline dietary assessment indicative of 28% or less daily calories from fat * Inability to comply with the protocol (many meals per week eaten outside of the home, frequent travel) * Pregnancy or planned pregnancy within next 6 months at time of screening * HbA1C \>6.5%

Design outcomes

Primary

MeasureTime frame
Urinary Pregnadiol Glucouronide concentration in ug/mg creatinineFrom enrollment for 4 months post enrollment

Secondary

MeasureTime frameDescription
Amount of Urinary estrogenFrom enrollment to 4 monthsUrinary estrogen concentration in microgram/mg of Creatinine

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026